BEAM

Beam TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$43.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$29.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$13.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-02

AI commentary

Primary clinical evidence remains constructive, but BEAM-302's pivotal outcome is unresolved. The $24.39 October 1 anchor is about 0.5% above the prior baseline's $24.27 September 25 anchor; the packet does not establish why shares moved. Recent litigation coverage adds a risk to monitor, not a proven operating setback. Analyst revisions, options positioning, short interest, employee sentiment and sufficiently covered social sentiment were unavailable; zero fields denote missing measurements, not neutral readings.

RankAlpha Sentiment Codex - 2026-10-02

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventRisto-cel data and potential BLA submissionHigh impact

Beam says dosing is complete for adult and adolescent patients in the BEACON sickle-cell trial. It expects updated data by year-end 2026 and a U.S. BLA submission as early as year-end; timing and regulatory sufficiency remain uncertain [#8-K-2026-08-04][#SEC-8K-2026-08-04]. Source: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm

2026-12-31eventInitial BEAM-301 clinical dataHigh impact

Beam expects initial 2026 clinical data from its Phase 1/2 BEAM-301 trial in glycogen storage disease type Ia. An early human safety and activity signal could broaden confidence in its liver-targeted platform, but a small dataset may be inconclusive [#SEC-8K-2026-08-04]. Source: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-ex99_1.htm

2027-06-30catalystBEAM-302 pivotal-cohort progressHigh impact

Beam reported that BEAM-302 raised mean circulating AAT to 14.4 µM from 5.0 µM at baseline in the Part A 60 mg cohort and that dosing is underway in an approximately 50-patient pivotal cohort. Enrollment, safety and 12-month biomarker results remain the tests of its proposed accelerated-approval path; FDA agreement is not assured [#IR-2026-09-08]. Source: https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-updated-clinical-data-phase-12-trial

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-02 • Updated nightlySource: Internal modelMethodology